Moximed is commercializing the KineSpring®, a medical implant for patients suffering from osteoarthritis of the knee.

Osteoarthritis is the most common form of arthritis and affects an estimated 150 million people worldwide. The KineSpring® is designed to unload excess weight on the knee. It is therefore suited for a growing population of patients that are too young to receive knee replacement surgery. To date, over 600 patients have received a KineSpring® implant.

After Gilde invested in Moximed, the company started to commercialize its products in Europe and established a multinational user-base. It has further initiated clinical studies for market registration in the US and optimized the implant, procedure and surgical instruments. Moximed is based in Hayward, California.